Evaluation of copper-64-labeled somatostatin agonists and antagonist in SSTr2-transfected cell lines that are positive and negative for p53: implications for cancer therapy

This publication has 46 references indexed in Scilit:

• Agonist-Biased Signaling at the sst2A Receptor: The Multi-Somatostatin Analogs KE108 and SOM230 Activate and Antagonize Distinct Signaling Pathways
  Molecular Endocrinology, 2010
• Preparation and Biological Evaluation of ⁶⁴Cu-CB-TE2A-sst₂-ANT, a Somatostatin Antagonist for PET Imaging of Somatostatin Receptor–Positive Tumors
  Journal of Nuclear Medicine, 2008
• Nuclear Uptake and Dosimetry of 64Cu-Labeled Chelator Somatostatin Conjugates in an SSTr2-Transfected Human Tumor Cell Line
  Journal of Nuclear Medicine, 2007
• Radiolabeled somatostatin receptor antagonists are preferable to agonists forin vivopeptide receptor targeting of tumors
  Proceedings of the National Academy of Sciences, 2006
• Receptor Signaling and Endocytosis Are Differentially Regulated by Somatostatin Analogs
  Molecular Pharmacology, 2005
• First 18F-Labeled Tracer Suitable for Routine Clinical Imaging of sst Receptor-Expressing Tumors Using Positron Emission Tomography
  Clinical Cancer Research, 2004
• Live or let die: the cell's response to p53
  Nature Reviews Cancer, 2002
• Expression of somatostatin receptor subtypes and growth inhibition in human exocrine pancreatic cancers
  Journal of Hepato-Biliary-Pancreatic Surgery, 2000
• Efficient production of high specific activity 64Cu using a biomedical cyclotron
  Nuclear Medicine and Biology, 1997
• Similar Lethal Effect in Mammalian Cells for Two Radioisotopes of Copper with Different Decay Schemes,⁶⁴Cu and⁶⁷Cu
  International Journal of Radiation Biology, 1989